Diabetes mellitus and chronic kidney disease: A neglected and dangerous liaison

Niessner A Tamargo J Koller L , et al. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: A position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J 2018; 39: 2274–2281.

Cosentino F Grant PJ Aboyans V , et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255–323.

European Medicines Agency. CPMP/EWP/1080/00 Rev. 1. Committee for Medicinal Products for Human Use (CHMP). www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus-revision_en.pdf (accessed 25 February 2020).

Pulipati VP Ravi V and Pulipati P. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Eur J Prev Cardiol, 2020; 27: 1922–1930.

Marso SP Daniels GH Brown-Frandsen K , et al . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–322.

Marso SP Bain SC Consoli A , et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834–1844.

Wanner C Inzucchi SE Lachin JM , et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323–334.

Neal B Perkovic V Mahaffey KW , et al . Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.

Wiviott SD Raz I Bonaca MP , et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347–357.

Jardine MJ Mahaffey KW Neal B , et al . The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 2017; 46: 462–472.

Diabetes Prevention Program Research Group, Knowler WC Fowler SE , et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677–1686.